180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company is headquartered in Palo Alto, California. The company went IPO on 2017-06-07. The firm is focused on iGaming sector, through its iGaming Technology Platform. The firm also continues to evaluate monetization strategies for its biotechnology assets.
ATNF stock price ended at $0 on 月曜日, after dropping NaN%
On the latest trading day Aug 24, 2026, the stock price of ATNF fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for ATNF decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.